Researchers at the institute are developing several cellular and biologic therapies to prevent and treat type 1 and type 2 diabetes, as well as to prevent the rejection of transplanted tissues and organs.
Among the therapies that are in various stages of development:
Autologous tolerogenic dendritic cell therapy for type 1 diabetes, where a special population of white blood cells, expanded from the blood of the patients themselves, is given back to them to reset their immune system in order to limit or completely stop the autoimmune attack against their own insulin-producing cells of the pancreas.
Tolerogenic nanoparticle vaccines for type 1 diabetes to reprogram white blood cells inside a patient so that the autoimmune destruction of the insulin-producing cells in the pancreas is prevented or shut down.
Engineered thymic cell mini-organoids, which reconfigure the population of T-cells into a new state, which re-establishes the immune system of the patient with an autoimmune disease to interact normally, and not reject the disease target organ. A reconstructed “hybrid” thymus is also opening up the possibility of recognizing foreign tissue and organ transplants as “self,” reducing or totally eliminating the need for immunosuppression.
Inflammation-sensitive nanoparticles that release immunosuppressive drugs and biologics useful to control and suppress autoimmunity, selectively inside the region of active inflammation, and eliminate the bystander and systemic side effects.
Modulators of rapid-onset and innate immunity inserted as transgenes into the donor tissues to prevent the destructive early rejection processes involved in xenotransplantation (the transplant into humans of non-human tissues and organs) in order to increase the likelihood of success of conventional immunosuppressive treatment.
Neutrophil-modifying bio-agents to prevent the inflammation that underlies metabolic syndromes, which lead to uncontrolled blood glucose, with type 2 diabetes as the primary disease target.
